Dechra Pharmaceuticals PLC Annual Report and Accounts for the year ended 30 June 2021
Our Purpose
and Strategy
Our Purpose
What we do
The sustainable improvement of animal health and welfare globally
Our Purpose
Why we exist
The sustainable improvement of animal health and welfare globally
Our Approach to ESG
Our ESG strategy is based on our Purpose and Values
We have chosen to support the United Nations Sustainable Development Goals (SDGs).
Our Strategy
How we achieve our purpose
Strategic Growth Drivers
Pipeline
Delivery
Portfolio
Focus
Geographical
Expansion
Acquisition
Strategic Enablers
Manufacturing &
Supply Chain
Technology
People
ESG
Our Values
Fundamental beliefs that underpin everything we do
Dedication
Enjoyment
Courage
Honesty
Relationships
Ambition
Our Culture
Ethical foundation enabling better decisions every day
Our Values, entrepreneurial attitude and agile approach to the way we do things are the backbone of our Culture.
We expect our people to make a difference by collaborating with each other and we support them by providing clear guidance on expectations.
Our Products
Our products can be divided into four categories, as set out below. All are targeted at providing veterinary professionals with solutions for their customers’ needs.
Companion Animal Products (CAP)
Species: Dogs and cats
Key therapeutic sectors: Endocrinology, dermatology, analgesia and anaesthesia, antiobiotics, cardiovascular and critical care.
72.8% of Group Revenue
Food producing Animal Products (FAP)
Species: Poultry, pigs and an increasing presence in cattle.
Key therapeutic sectors: Water soluble antibiotics, poultry vaccines, locomotion (lameness) and pain management.
12.7% of Group Revenue
Equine
Species: Horses and ponies
Key therapeutic sectors: Locomotion (lameness) and pain management.
7.3% of Group Revenue
Nutrition
Species: Dogs and cats.
Key therapeutic sectors: Our pet diets are available to support the wellbeing of animals with numerous therapeutic conditions.
5.2% of Group Revenue
Our Product Pipeline
A key strategic priority for the Group is the delivery and strength of the pipeline. We currently have 33 projects in the product development process:
Our Global Footprint
We currently have sales and marketing organisations in 25 countries and market our products in 68 other countries worldwide through distributors or marketing partners.
Manufacturing Sites
Logistics Sites
Sales and Marketing
Distribution Partners
North America
36.1%
of Group Revenue by Region
Dechra Veterinary Products markets and sells Dechra’s products via its own sales and marketing organisations or via distributors across Canada, Mexico and the USA, the latter being the world’s largest animal health market. In addition, there are manufacturing sites in Florida and Texas. Product Development and Regulatory Affairs teams are also located in the three countries.
Major geographies: United States
Europe
51.9%
of Group Revenue by Region
Dechra Veterinary Products markets and sells Dechra’s products in 41 countries either via its own sales and marketing organisations or via distributors. Its main distribution centre is in Denmark. There are manufacturing sites and Product Development and Regulatory Affairs teams in Croatia, the Netherlands and the UK.
Major geographies: France, Germany, the Netherlands and the UK
Rest of the World
12.0%
of Group Revenue by Region
Dechra has manufacturing facilities and a Product Development and Regulatory Affairs presence in Australia and Brazil. Dechra Veterinary Products markets and sells Dechra’s products in 39 countries either via its sales and marketing organisations (Australia, New Zealand (ANZ) and Brazil) or via distributors.
Major geographies: Australia, New Zealand, Asia and Brazil
Downloads